Becton Dickinson (BDX) Q4 2025 Earnings Transcript

Becton Dickinson reported Q4 revenue of $5.9 billion, up 7% and 3.9% organic, with adjusted EPS of $3.96 and full-year EPS of $14.40, up 9.6% despite a tariff headwind. Management guided fiscal 2026 EPS to $14.75-$15.05 and revenue to low-single-digit growth, while embedding headwinds from vaccines, China VoBP, Alaris comparisons, and $185 million of tariff costs. The company also highlighted a Waters transaction expected to close by Q1 2026 and plans to return at least half of the $4 billion proceeds via buybacks, alongside a $250 million repurchase this quarter.

Analysis

BDX is transitioning from a “prove-the-turnaround” story into a self-help compounder: the market is likely underappreciating how much of the guide compression is intentional, not cyclical. With a large share of the portfolio now insulated by consumables and recurring installs, near-term headline growth can look mediocre while the earnings base quietly de-risks through mix, productivity, and buybacks. The cleaner signal is that management is effectively monetizing lower-quality businesses at a premium multiple and reallocating capital into a higher-return, higher-visibility MedTech core.

The more important second-order effect is competitive: the new commercial structure and targeted sales-force expansion should pressure smaller point-solution rivals in adjacent niches where BD can bundle installed base, service, and procurement relationships. That matters most in APM, PureWick, and dispensing, where the company can turn operational scale into share gains faster than peers can replicate. The flip side is that guidance has been built on a lot of self-imposed conservatism, so any stabilization in China or vaccines is optionality rather than baseline.

On risk, tariffs are a near-term margin tax but not the real issue; the real risk is that investors misread the next two quarters as a growth stall and de-rate the stock before the buyback and Waters proceeds hit. The first catalyst window is 1Q26 earnings, where softness is most visible but should also mark the trough in phasing. Over a 6–12 month horizon, the combination of cost-out, pricing/mix, and repurchase accretion creates a setup for EPS inflection even if organic growth stays only mid-single digits.

Contrarian view: the market is likely too focused on the optics of low- to mid-single-digit revenue and too little on the implied FCF yield once Waters closes. If the deal clears and the company executes the stated buyback cadence, the stock likely re-rates on capital return and earnings durability rather than top-line acceleration. The main reason to be cautious is that the thesis depends on management credibility around execution in commercial redesign and on not over-discounting the tax-rate step-up in the pro forma New BD.

Key Decisions for Investors

• Long BDX on a 6–12 month horizon; use any post-1Q26 weakness to add, as the near-term revenue trough should precede buyback accretion and margin lift. Risk/reward: asymmetric if the stock stays de-rated near ~10x pro forma earnings while FCF and repurchases compound.
• Buy BDX Jan-2027 calls or call spreads to express upside from the Waters close + buyback program without paying full equity carry. Best entry is after a weak 1Q26 print, when implied volatility should reset lower but execution risk remains mispriced.
• Pair trade: long BDX / short a basket of slower-growing medtech peers with weaker recurring revenue and less capital return visibility. The thesis is relative re-rating as investors reward capital allocation discipline and punish businesses still reliant on pure organic growth.
• Avoid chasing WAT into deal-close; consider it as a temporary event-driven hedge only if merger spread widens. The better expression is owning BDX into the close, since the accretive capital return and portfolio simplification sit on the parent side.
• If tariffs or China headline risk causes a sharp selloff over the next 1–2 quarters, use that dislocation to size up—these are timing risks, not thesis breakers, unless gross margin expansion stalls for two consecutive quarters.